title: Triamcinolone Acetonide and Bevacizumab Induced Raised Intraocular Pressure in An Elderly Male Diabetic Patient - A Case Report.
abstract: Intravitreal triamcinolone and bevacizumab are emerging treatment modalities for the patients of macular oedema; however, they are known to raise intraocular pressure. A 61 year old diabetic male patient developed glaucoma after administration of triamcinolone acetonide and bevacizumab intravitreally for treatment of macular oedema. His intraocular pressure was raised up to about 42 mm Hg. Such high and sustained rise in intraocular pressure may lead to vision loss by damaging the optic nerve. The patient was managed by local as well as systematic therapy and was recovered after 1 month from the occurrence of an event. Intraocular pressure should be monitored in patients receiving intravitreal triamcinolone and bevacizumab. Risk benefit analysis must be done before using IVTA and IVB in patients with diabetic macular oedema.
authors.forename: Hiral N
authors.initials: HN
authors.lastname: Golakiya
authors.forename: Hiren N
authors.initials: HN
authors.lastname: Hirapara
authors.forename: Sugnesh J
authors.initials: SJ
authors.lastname: Parmar
authors.forename: Viren N
authors.initials: VN
authors.lastname: Naik
authors.affiliation: Department of Pharmacology, Government Medical College, Bhavnagar 364001 (Gujarat), India.
authors.forename: Chandrabhanu B
authors.initials: CB
authors.lastname: Tripathi
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D000068258:Bevacizumab / Q000008:administration & dosage / Q000009:adverse effects*; D003920:Diabetes Mellitus / Q000175:diagnosis / Q000188:drug therapy*; D005901:Glaucoma / Q000139:chemically induced / Q000175:diagnosis; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects* / Q000502:physiology; D058449:Intravitreal Injections / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D014222:Triamcinolone Acetonide / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D020533:Angiogenesis Inhibitors; D005938:Glucocorticoids; D000068258:Bevacizumab; D014222:Triamcinolone Acetonide